Literature DB >> 34288806

Identification and monitoring of Copy Number Variants (CNV) in monoclonal gammopathy.

Fabio Sallustio1, Claudia Curci2, Antonio Giovanni Solimando3,4, Patrizia Leone3, Paola Pontrelli5, Loreto Gesualdo5, Angelo Vacca3, Vito Racanelli3, Anna Gallone1.   

Abstract

Monoclonal gammopathy of undetermined significance (MGUS) represents the pre-clinical stage of Multiple Myeloma (MM) with the 5% of MGUS progresses to MM. Although the progression from MGUS to MM has not been completely characterized, it is possible to monitor the DNA modifications of patients diagnosed with MGUS to detect early specific genomic abnormalities, including copy number variations (CNV). The CNVs of chromosome 1q and chromosome 13q are associated with a worse prognosis in MM.In the present study, we showed that it is possible to monitor the 1q21 gain and 13q deletion frequencies in gDNA using digital PCR. The CNV analysis of three cell lines with a well-characterized cytogenetic profile were compared with measures performed by a real-time PCR approach and with a digital PCR approach. Then, we analyzed CNVs in CD138+ plasma cells isolated from bone marrow of MGUS and MM patients.Our results show that digital PCR and targeted DNA monitoring represent a specific and accurate technique for the early detection of specific genomic abnormalities both in MM and in MGUS patients.Our results could represent a remarkable advancement in MM and MGUS diagnosis and in CNV analysis for the evaluation of the risk of progression from MGUS to MM.

Entities:  

Keywords:  CNVs detection; MGUS; MM; digital PCR

Mesh:

Year:  2021        PMID: 34288806      PMCID: PMC8386727          DOI: 10.1080/15384047.2021.1946458

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.875


  40 in total

1.  Digital PCR: Principles and Applications.

Authors:  Rashmi Kanagal-Shamanna
Journal:  Methods Mol Biol       Date:  2016

2.  Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value.

Authors:  Gang An; Yan Xu; Lihui Shi; Zhong Shizhen; Shuhui Deng; Zhenqing Xie; Weiwei Sui; Fenghuang Zhan; Lugui Qiu
Journal:  Haematologica       Date:  2013-11-08       Impact factor: 9.941

3.  Salvage therapy with lenalidomide and dexamethasone in relapsed primary plasma cell leukemia.

Authors:  Pellegrino Musto; Giuseppe Pietrantuono; Roberto Guariglia; Oreste Villani; Maria Carmen Martorelli; Fiorella D'Auria; Antonia Zonno; Rosa Lerose
Journal:  Leuk Res       Date:  2008-04-22       Impact factor: 3.156

4.  International staging system for multiple myeloma.

Authors:  Philip R Greipp; Jesus San Miguel; Brian G M Durie; John J Crowley; Bart Barlogie; Joan Bladé; Mario Boccadoro; J Anthony Child; Herve Avet-Loiseau; Jean-Luc Harousseau; Robert A Kyle; Juan J Lahuerta; Heinz Ludwig; Gareth Morgan; Raymond Powles; Kazuyuki Shimizu; Chaim Shustik; Pieter Sonneveld; Patrizia Tosi; Ingemar Turesson; Jan Westin
Journal:  J Clin Oncol       Date:  2005-04-04       Impact factor: 44.544

Review 5.  International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

Authors:  S Vincent Rajkumar; Meletios A Dimopoulos; Antonio Palumbo; Joan Blade; Giampaolo Merlini; María-Victoria Mateos; Shaji Kumar; Jens Hillengass; Efstathios Kastritis; Paul Richardson; Ola Landgren; Bruno Paiva; Angela Dispenzieri; Brendan Weiss; Xavier LeLeu; Sonja Zweegman; Sagar Lonial; Laura Rosinol; Elena Zamagni; Sundar Jagannath; Orhan Sezer; Sigurdur Y Kristinsson; Jo Caers; Saad Z Usmani; Juan José Lahuerta; Hans Erik Johnsen; Meral Beksac; Michele Cavo; Hartmut Goldschmidt; Evangelos Terpos; Robert A Kyle; Kenneth C Anderson; Brian G M Durie; Jesus F San Miguel
Journal:  Lancet Oncol       Date:  2014-10-26       Impact factor: 41.316

6.  Gain of chromosome arm 1q in patients in relapse and progression of multiple myeloma.

Authors:  Jana Balcárková; Helena Urbánková; Vlastimil Scudla; Milena Holzerová; Jaroslav Bacovský; Karel Indrák; Marie Jarosová
Journal:  Cancer Genet Cytogenet       Date:  2009-07-15

7.  Subcutaneous immunoglobulins in patients with multiple myeloma and secondary hypogammaglobulinemia: a randomized trial.

Authors:  Angelo Vacca; Assunta Melaccio; Azzurra Sportelli; Antonio G Solimando; Franco Dammacco; Roberto Ria
Journal:  Clin Immunol       Date:  2017-11-28       Impact factor: 3.969

8.  Halting the vicious cycle within the multiple myeloma ecosystem: blocking JAM-A on bone marrow endothelial cells restores angiogenic homeostasis and suppresses tumor progression.

Authors:  Antonio G Solimando; Matteo C Da Vià; Patrizia Leone; Paola Borrelli; Giorgio A Croci; Paula Tabares; Andreas Brandl; Giuseppe Di Lernia; Francesco P Bianchi; Silvio Tafuri; Torsten Steinbrunn; Alessandra Balduini; Assunta Melaccio; Simona De Summa; Antonella Argentiero; Hilka Rauert-Wunderlich; Maria A Frassanito; Paolo Ditonno; Erik Henke; Wolfram Klapper; Roberto Ria; Carolina Terragna; Leo Rasche; Andreas Rosenwald; Martin K Kortüm; Michele Cavo; Domenico Ribatti; Vito Racanelli; Hermann Einsele; Angelo Vacca; Andreas Beilhack
Journal:  Haematologica       Date:  2021-07-01       Impact factor: 9.941

9.  Comparison of microfluidic digital PCR and conventional quantitative PCR for measuring copy number variation.

Authors:  Alexandra S Whale; Jim F Huggett; Simon Cowen; Valerie Speirs; Jacqui Shaw; Stephen Ellison; Carole A Foy; Daniel J Scott
Journal:  Nucleic Acids Res       Date:  2012-02-28       Impact factor: 16.971

Review 10.  High-Risk Multiple Myeloma: Integrated Clinical and Omics Approach Dissects the Neoplastic Clone and the Tumor Microenvironment.

Authors:  Antonio Giovanni Solimando; Matteo Claudio Da Vià; Sebastiano Cicco; Patrizia Leone; Giuseppe Di Lernia; Donato Giannico; Vanessa Desantis; Maria Antonia Frassanito; Arcangelo Morizio; Julia Delgado Tascon; Assunta Melaccio; Ilaria Saltarella; Giuseppe Ranieri; Roberto Ria; Leo Rasche; K Martin Kortüm; Andreas Beilhack; Vito Racanelli; Angelo Vacca; Hermann Einsele
Journal:  J Clin Med       Date:  2019-07-09       Impact factor: 4.241

View more
  1 in total

1.  Prognostic Value of Association of Copy Number Alterations and Cell-Surface Expression Markers in Newly Diagnosed Multiple Myeloma Patients.

Authors:  Mihaiela L Dragoș; Iuliu C Ivanov; Mihaela Mențel; Irina C Văcărean-Trandafir; Adriana Sireteanu; Amalia A Titianu; Angela S Dăscălescu; Alexandru B Stache; Daniela Jitaru; Dragoș L Gorgan
Journal:  Int J Mol Sci       Date:  2022-07-07       Impact factor: 6.208

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.